Enveric hires firm to contest post-grant review petition filed by Gilgamesh

Enveric Biosciences (ENVB) announced that it has hired Fish and Richardson P.C. to contest a post-grant review petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 entitled, “Halogenated psilocybin derivatives and methods of using.” Enveric’s ‘276 patent includes claims that appear relevant to the Bretisilocin molecule currently in clinical trials, which AbbVie (ABBV) agreed to acquire on August 25 in a definitive transaction valued at up to $1.2B. The Gilgamesh PGR petition specifically targets claims that may be relevant to Bretisilocin and other claims of the ‘276 patent. Enveric’s ‘276 patent family also includes one additional issued U.S. patent, a pending U.S. application, and related international patent applications in Australia, Canada, China, Europe, Japan, Mexico, and South Korea. The Enveric ‘276 patent family does not cover the pipeline of Enveric’s proprietary therapeutic candidates, such as EB-003, which are protected under separate, distinct patent families. Enveric’s intellectual property portfolio, including the ‘276 patent family, includes 26 issued U.S. patents and a total of 60 pending national and international applications covering five programs.